Eva Fredriksson

Eva Fredriksson has a diverse and extensive work experience. Eva started their career as a Congress and Meetings employee at Eli Lilly and Company in 2009. Eva then moved on to roles such as Project Leader at Thermo Fisher Scientific, where they led a project focused on personalized diagnostics for Multiple sclerosis and Rheumatoid arthritis.

Eva later worked as a Market Analyst at Accelerator Nordic AB, where they developed a business strategy and promotional material for a drug used in Percutan Coronary Intervention.

At Natumin Pharma AB, Eva served as a Global Product Manager in the field of dermatology, responsible for product strategy, market activities, launches, and pricing.

Eva also worked at Roche as an Associate Product Manager, promoting a new launch of a biological pharmaceutical in the field of rheumatology.

Eva then co-founded CoGig, a unique employer branding and recruitment company, where they focused on business development, sales, and marketing.

Eva'smost recent role was as the Business Unit Head at Perrigo Company plc, where they were responsible for the pharmaceutical portfolio, developing new business, and leading cross-functional teams.

Throughout their career, Eva has demonstrated strong leadership skills, strategic thinking, and the ability to build successful teams and partnerships.

Eva Fredriksson's education history includes a Master of Science in Biotechnology from KTH Royal Institute of Technology, which they completed from 2004 to 2009. During this time, they focused on the field of engineering. In 2013, Eva pursued an IMA and LIF degree, but the degree name and field of study are not specified. In 2008, they took courses in Pharmaceutical Engineering, Genetics II A: Foundation of Genetics, and Professional English at the University of Adelaide. Eva also attended Uppsala University in 2009, where they studied Business and Entrepreneurship development. Lastly, in 2022, Eva completed a program in Market Access, but the degree name and field of study are not provided.